Literature DB >> 7086144

Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.

L F Qualtiere, R Chase, G R Pearson.   

Abstract

The Epstein Barr virus membrane antigen (MA) complex is composed of three major high m.w. glycoproteins designated gp 300/350, gp 200/250, and gp 85/90. In the experiments reported in this paper, the gp 300/350 glycoprotein was purified from MA-positive extracts prepared from the B-95-8 cell line. This was accomplished by tandem combination of ion-exchange and lectin chromatography. It was routinely possible to purify this glycoprotein 400- 600-fold by this procedure. Sera from animals immunized with gp 300/350 purified by this approach neutralized EBV infectivity and mediated antibody-dependent cellular cytotoxicity (ADCC) demonstrating that both of these important antigenic determinants were expressed on this glycoprotein. The presence of an ADCC determinant on this molecule was further substantiated by the finding that monoclonal antibody to gp 300/350 blocked ADCC mediated by a human ADCC antibody-positive reference serum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

2.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

5.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

8.  Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen.

Authors:  R Fox; R Sportsman; G Rhodes; J Luka; G Pearson; J Vaughan
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

9.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.

Authors:  M T Bejarano; M G Masucci; A Morgan; B Morein; G Klein; E Klein
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.